Stem cell research conflict bill moves a step closer to ballot
By Knight Ridder,
Knight Ridder
| 05. 19. 2005
A measure to strengthen conflict-of-interest rules on Proposition 71-funded stem cell research cleared a second legislative hurdle Wednesday, even as critics warned it would scare off scientists.
The bill, SCA13, co-authored by Sens. Deborah Ortiz, D-Sacramento, and George Runner, R-Lancaster, passed the Senate committee on elections on a 5-0 vote. It is due to be considered next in the Senate Appropriations Committee on Monday.
The legislation would require the agency set up by Proposition 71, the measure voters approved in the fall to provide $3 billion toward stem cell research, to follow standards recently applied to the National Institutes of Health.
Those rules forbid employees from holding biotech or pharmaceutical stocks. SCA13 would extend the regulations to the California Institute for Regenerative Medicine, the agency overseeing the research, and its advisory groups.
To become law, the constitutional amendment must receive a two-thirds majority from both houses of the Legislature and be passed by the state's voters.
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
